Athenex Investor Relations Material
Latest events
Q3 2022
Athenex
Q4 2022
20 Mar, 2023
Corporate Presentation
2 Jan, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Athenex Inc
Access all reports
Athenex, Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel cancer therapies. The company operates through two primary segments: the Oncology Innovation Platform and the Commercial Platform. Its research and development efforts are centered around proprietary cell therapy technologies, including its Natural Killer T-cell (NKT) therapy, aimed at treating cancer. Athenex also manages a commercial division that markets specialty pharmaceutical products, particularly in oncology and related fields. The company is headquartered in Buffalo, New York, and its shares are listed on the OTC market.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ATNX
Country
🇺🇸 United States